Semaglutide for Obesity

The U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Wegovy is the first weight loss medication to also be app… source↗

Wegovy: Authorised - This medicine is authorised for use in the European Union. Marketing authorisation date: 06 January 2022. The medicine can only be obtained with a prescription. Wegovy is used together with diet and physical activity to manage weight (including losing weight and keeping it off) in adults with a body mass index (BMI) of 30 kg/m2 or more (obesity) or in adults with a BMI of a… source↗

Semaglutide is recommended as an option for weight management, including weight loss and weight maintenance, alongside a reduced-calorie diet and increased physical activity in adults, only if: it is used for a maximum of 2 years, and within a specialist weight management service providing multidisciplinary management of overweight or obesity (including but not limited to tiers 3 and 4), and th… source↗

胰妥讚 注射劑 Ozempic solution for injection 衛部菌疫輸字第001107 號；主成分 Semaglutide 1.34mg/mL,3mL；適應症：用於第二型糖尿病成人病人作為飲食和運動之輔助療法，以單一療法或與其他糖尿病治療藥品併用方式，治療控制不佳之第二型糖尿病；對於第二型糖尿病合併已確診心血管疾病之病人，可降低主要不良心血管事件之風險。健保給付規定：限第二型糖尿病病人經 metformin 及/或 sulfonylurea 兩類藥品最大耐受劑量，及繼續使用下列藥品其中之一達 6 個月後 HbA1c 仍 ≥8.5% 者使用。 source↗

GLP-1 therapies may be used by adults, but excluding pregnant women, for the long-term treatment of obesity. [...] GLP-1 receptor agonists – semaglutide, dulaglutide and liraglutide [added to EML] for adults with type 2 diabetes mellitus with established cardiovascular disease or chronic kidney disease and obesity (defined as body mass index (BMI) ≥ 30kg/m2). [...] High prices of medicines like… source↗

Semaglutide (Ozempic, Wegovy, Rybelsus) is a prescription GLP-1 medication used for weight loss and weight management, type 2 diabetes treatment, or to reduce the risk of chronic kidney disease and major cardiovascular events in certain patients with type 2 diabetes. Semaglutide (Wegovy) is also used to treat metabolic dysfunction-associated steatohepatitis (MASH), without cirrhosis of the live… source↗

Wegovy® is FDA-approved for weight management. Based on a 68-week clinical trial, patients without diabetes but with a BMI of ≥30, or ≥27 lost an average of 15% of their body weight (-33.6 lbs) on 2.4 mg semaglutide, when combined with a reduced-calorie diet and increased physical activity. The Food & Drug Administration approved GLP-1s for weight loss as part of a weight management program. Th… source↗

Wegovy (semaglutide) is a weekly injection you take to lose weight. It's for adults with obesity or overweight. Wegovy is the only semaglutide approved by the FDA for weight loss. Wegovy may be the better choice for weight loss because it goes up to 2.4 mg weekly. Talk to your care team right away if you have a lump or swelling in your neck, hoarseness that does not go away, trouble swallowing,… source↗

the FDA announced the long-anticipated approval of Wegovy, an injectable medication taken once per week for weight management... approved for use in those with a body mass index (BMI) of 30 kg/m2 or greater, or those with a BMI of 27 kg/m2 with a weight-related medical condition... demonstrated an average of 14.9% body weight reduction after 68 weeks of therapy in those assigned to the medicati… source↗

GLP-1 therapies, including both single and combination agents, have emerged as powerful tools in the management of obesity, demonstrating average placebo-adjusted weight reductions of 5–18% in clinical trials, along with improvements in metabolic, functional and cardiovascular outcomes. source↗